Pre‐ and post‐bone marrow harvest anaemia is associated with lower CD34+ stem cell collection, high harvest volume and female gender

2020 ◽  
Vol 50 (3) ◽  
pp. 299-306
Author(s):  
Bartlomiej M. Getta ◽  
Daochen Tong ◽  
Stephanie Deren ◽  
Gillian Huang ◽  
Megan Hogg ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Female Gender ◽  
Harvest Volume ◽  
Stem Cell Collection

scholarly journals Prophylactic Peripheral Blood Stem Cell Collection in Patients with Extensive Bone-Marrow Infiltration of Neuroendocrine Tumours Prior to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE

2021 ◽  
Vol 14 (10) ◽  
pp. 1022
Author(s):  
Amir Sabet ◽  
Nicolai Mader ◽  
Jörg Thomas Bittenbring ◽  
Fadi Khreish ◽  
Frank Grünwald ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Peripheral Blood ◽  
Radionuclide Therapy ◽  
Peripheral Blood Stem Cell ◽  
Peptide Receptor Radionuclide Therapy ◽  
Blood Stem Cell ◽  
Peptide Receptor ◽  
Cell Mobilization ◽  
Stem Cell Collection

Peptide receptor radionuclide therapy (PRRT) of metastatic neuroendocrine tumors (NET) can be successfully repeated but may eventually be dose-limited. Since 177Lu-DOTATATE dose limitation may come from hematological rather than renal function, hematological peripheral blood stem cell backup might be desirable. Here, we report our initial experience of peripheral blood stem-cell collection (PBSC) in patients with treatment-related cytopenia and therefore high risk of bone-marrow failure. Five patients with diffuse bone-marrow infiltration of NET and relevant myelosuppression (≥grade 2) received PBSC before one PRRT cycle with 177Lu-DOTATATE (7.6 ± 0.8 GBq/cycle). Standard stem-cell mobilization with Granulocyte-colony stimulating factor (G-CSF) was applied, and successful PBSC was defined as a collection of >2 × 106/kg CD34+ cells. In case of initial failure, Plerixafor was administered in addition to G-CSF prior to apheresis. PBSC was successfully performed in all patients with no adverse events. Median cumulative activity was 44.8 GBq (range, 21.3–62.4). Three patients had been previously treated with PRRT, two of which needed the addition of Plerixafor for stem-cell mobilization. Only one of five patients required autologous peripheral blood stem-cell transplantation during the median follow up time of 28 months. PBSC collection seems to be feasible in NET with bone-marrow involvement and might be worth considering as a backup strategy prior to PRRT, in order to overcome dose-limiting bone-marrow toxicity.

Sternal bone marrow is a suitable autologous cell source for cardiac stem cell therapies

2014 ◽  
Vol 62 (S 01) ◽  
Author(s):  
M. Arar ◽  
A. Rotärmel ◽  
A.-K. Knoefel ◽  
H. Baraki ◽  
I. Kutschka ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Cardiac Stem Cell ◽  
Stem Cell Therapies ◽  
Cell Therapies ◽  
Autologous Cell ◽  
Cell Source
Sign in / Sign up

Export Citation Format

Share Document